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Purpose: The aim of this pilot validation study was to determine the accuracy of a smartphone 
(iPhone®) pedometer in adults with and without asthma. Methods: Ten adults with asthma and ten 
healthy controls underwent clinical assessment prior to completing two separate trials. Phase 1. 
standardised treadmill and self-paced walking tests. Total steps were recorded via: (i) Yamax 
Digiwalker™ SW800 pedometer positioned on the waistband, (ii) iPhone® pedometer positioned on 
the upper body, (iii) iPhone® pedometer positioned on the lower body and evaluated against a video-
verified manual step-count. Phase 2. step-count was evaluated over seven-days during habitual free-
living conditions via Yamax Digiwalker™ SW800 and iPhone® pedometers. Results: During treadmill 
walking, the iPhone® positioned on the lower body correlated strongly (r = 0.96) and produced the 
highest level of agreement (mean bias: -11 steps, LOA: -43 to 21 steps) in comparison to video-
verified manual step-count. During self-paced walking, all devices provided an excellent step-count 
estimate. During free-living conditions, no difference was observed between the Yamax Digiwalker™ 
SW800 pedometer and iPhone® (P = 0.10) and a strong correlation (r = 0.94) and acceptable 
agreement (mean bias: -343, LOA: -1963 to 1276 steps) was observed. Conclusion: Our findings 
indicate that an in-built iPhone® pedometer offers a practical approach to physical activity 
assessment in adults with and without asthma. Future research is now required to further validate 
the precision of this approach and evaluate the efficacy and effectiveness of smartphone 
pedometers to monitor and promote physical activity when employed during medical consultation 


















Asthma is a chronic inflammatory airways disease associated with airway hyperresponsiveness, 
bronchoconstriction and variable respiratory symptoms such as cough, wheeze, and dyspnoea. The 
disease affects approximately 350-million people worlwide [1] and remains a major source of global 
economic and societal burden [2]. Despite clear guidelines and even in the context of adequate 
health care provision, control is often sub-optimal with asthma symptoms and exacerbations being 
common and under reported [3]. For the most part, asthma management strategies focus on 
pharmacological intervention with a stepwise approach to treatment escalation according to local, 
national and international guidelines [4]. While this approach is effective in most cases, the adverse 
side effects associated with long-term therapy can be significant [5, 6] and adjunctive treatments 
which can help improve asthma control and minimise complications should be considered when 
optimising care. 
Physical activity has the potential of providing affordable and accessible adjunct approach to asthma 
management and related co-morbidities (e.g. obesity and cardiovascular disease etc.) with recent 
systematic reviews and meta-analyses reporting an association between the duration of activity, 
improved symptomology, slower lung function decline, higher functional capacity and lower systemic 
inflammation [7-9]. However, previous studies have relied primarily on patient recall when 
evaluating physical activity in people with airways disease (i.e. self-report and/or questionnaires) and 
this can be prone to both over and underestimation [10].  
The optimal method of measuring physical activity currently remains debated [11]. Although 
objective devices such as accelerometers and pedometers (i.e. step-counters) are widely endorsed 
for assessment, they have substantial limitations. For example, measurement error can arise through 
participant reactivity (i.e. behaviour changes in response to being observed). Equally, the high 
associated cost of the technology often precludes implementation in physical activity promotion 











Over the past decade there have been dramatic advances in mobile technologies and an exponential 
growth in smartphone devices (>3.5 billion users worldwide) [12] with in-built activity sensors (i.e. 
functionality to monitor daily step-count) which provides a pragmatic alternative approach to 
physical activity assessment. Although the validity and application of smartphones pedometers have 
previously been reported in healthy cohorts [13], there are little data on their use in people with 
asthma to measure habitual physical activity (i.e. total distance covered and time spent active) which 
is often significantly reduced and may impact and/or be an indirect measure of asthma control [7].  
The aim of this pilot validation study was therefore to determine the accuracy of a smartphone 
(Apple® iPhone - version 6 onwards) to quantify step-count in adults with and without asthma. We 
hypothesised that an in-built pedometer would provide a practical approach to physical activity 
assessment (i.e. valid step-count estimate) during laboratory and self-paced walking challenges and 














Study population and experimental design 
Twenty adults (male: n = 12) were enrolled into the study; ten adults with a prior physician-based 
asthma diagnosis prescribed ‘as-needed’ reliever and daily low dose ICS maintenance therapy and 
ten asymptomatic healthy controls with no prior history of airways disease or inhaler medication use 
(matched for age, gender and body mass index (BMI)). At study entry, all participants completed pre-
participation American College of Sports Medicine (ACSM) health screening [14] and underwent 
clinical assessment prior to completing two separate trials: treadmill and self-paced walking 
challenges (Phase 1) and habitual free-living conditions (Phase 2) (protocols detailed below). A 
standard Apple® iPhone (version 6 onwards) was used to quantify step-count for all trials. The study 
was approved by research ethics committee (ID: 61792) and all participants provided written 
informed consent. Clinical assessment and baseline pulmonary function  
The Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ) was 
completed by participants with asthma to evaluate symptom burden and disease specific health-
related quality of life [15, 16]. The Dyspnoea-12 (D-12) questionnaire was employed to characterise 
the physical and affective aspects of breathlessness and to ensure healthy controls had an entirely 
normal D-12 score (i.e. confirming their asymptomatic status) [17]. Lung function was assessed by 
maximal forced flow-volume spirometry (MicroLoop ML3535; Cardinal Health, Basingstoke, UK) and 
airway inflammation was evaluated via fractional exhaled nitric oxide (FeNO) using a hand-held 
measuring device (NIOX VERO; Aerocrine AB, Stockholm, Sweden) with established reference values 
employed in accordance with international guidelines [18, 19] . Body composition was determined 
via bioelectrical impedance analysis (Tanita, 330ST, Japan).  
Phase 1: Treadmill and self-paced walking challenges 
Participants completed a standardised treadmill test (Woodway PPS55 Med, Germany) consisting of 
3 x 3-minute stages at pre-determined speeds: low (2.5kph); moderate (5.0kph); high (7.5kph) at a 












tests, total steps were recorded using the following devices: (i) Yamax Digiwalker™ SW800 
pedometer positioned on the waistband, (ii) iPhone® pedometer positioned on the upper body 
(armband), (iii) iPhone® pedometer positioned on the lower body (trouser pocket) and evaluated 
against a video-verified manual step-count conducted by the investigator (CR). 
Phase 2: Habitual free-living conditions  
Total step-count was evaluated over a seven-day period during habitual free-living conditions via 
Yamax Digiwalker™ SW800 pedometer (criterian measure) and iPhone® pedometer. Participants 
were instructed to maintain their usual daily activities and were provided with a logbook to record 
hours spent active and total daily step-count. Participants were required to carry the devices on their 
person for a minimum of 10-hours per day [20].  
Statistical analysis 
Data are presented as mean (SD) or median (IQR) for continuous outcomes dependent on normality. 
An unpaired and paired samples t-test was employed to evaluate between and within group 
differences, respectively. Intra-class correlation coefficient (ICC) was calculated using a two-way 
mixed effect model with the mean single measure reported. Reproducibility was assessed (i.e. video-
verified manual step-count vs. pedometer) using the method described by Bland and Altman with 
difference expressed as mean bias (i.e. mean difference between group measures) and upper and 
lower 95% limits of agreement [21]. Linear regression was conducted to evaluate proportional bias 
between mean differences in devices. Data was analysed using SPSS Statistics 24 statistical software 
package (SPSS Inc., Version 26, Chicago, IL) and GraphPad Prism Version 8.0 (GraphPad Software, San 














Respiratory symptoms and baseline pulmonary function  
Of the ten participants with asthma, five had an ACQ score >1 (i.e. indicating inadequate asthma 
control). Of these, three had an AQLQ score <6 (i.e. indicating impaired quality of life). Two 
participants with an ACQ score <1 (i.e. well-controlled asthma) had an AQLQ score <6. The majority 
of participants (90%) had normal resting lung function with no evidence of expiratory airflow 
limitation (FEV1 predicted >80% and FEV1/FVC >70% predicted). Although participants with asthma 
had a lower FEV1 % predicted (P = 0.008), no difference was observed for any other pulmonary 
function parameter. Clinical characteristics are presented in Table 1. 
Phase 1: Treadmill walking challenge 
No difference was observed in video-verified total manual step-count between participants with 
asthma (1018 ± 54 steps) and healthy controls (1038 ± 58 steps) (P = 0.44) and therefore group data 
was pooled for analysis (mean: 1028 ± 56 steps). The Yamax Digiwalker™ SW800 pedometer 
correlated poorly (r = 0.37) with video-verified total manual step-count and produced wide limits of 
agreement (mean bias: -74 steps, LOA: -203 to 55 steps) at the lowest walking speed (2.5kph) 
(P<0.0001), yet provided an acceptable step-count estimate at moderate (5.0kph) and high (7.5kph) 
speeds.  
In contrast, the iPhone® positioned on either the upper or lower body provided a valid step-count 
estimate across all walking speeds. Although the iPhone® under-reported for most test stages when 
compared with video-verified total manual step-count (P<0.05), the absolute difference in step-count 
was negligible (range: -4 to -11 steps). For total step-count, the iPhone® (upper and lower) and 
Yamax Digiwalker™ SW800 pedometer had a percentage error of 2%, 1% and 8%, respectively. 
Specifically, the iPhone® positioned on the lower body (1017 ± 58 steps) correlated strongly (r = 0.96) 
and produced the highest level of agreement (mean bias: -11 steps, LOA: -43 to 21 steps) in 












Yamax Digiwalker™ SW800 pedometer (F = 11.47, P = 0.003) but not for the iPhone® lower body (F = 
0.36, P = 0.56) or iPhone® upper body (F = 1.24, P = 0.28) (Table 2). 
Phase 1: Self-paced walking challenge 
Visual inspection of the data indicated a significant outlier (>20% difference between devices and 
video-verified total manual step-count) and thus nineteen participants were included in the analysis 
(asthma: n = 9; healthy controls: n = 10). No significant difference was observed in video-verified 
total manual step-count between participants with asthma (1390 ± 168 steps) and healthy controls 
(1420 ± 131 steps) (P = 0.67) and therefore group data was pooled for analysis (mean: 1406 ± 146 
steps). The iPhone® (upper and lower body) and Yamax Digiwalker™ SW800 pedometer had a 
percentage error of 1%, 0% and 1%, respectively. Although the strongest correlation (r = 0.99) and 
highest level of agreement was observed for iPhone® upper (mean bias: -4 steps, LOA: -49 to 41 
steps), all devices provided an excellent step-count estimate during self-paced walking (Figure 4). 
Proportional bias was not identified for any of the devices: Yamax Digiwalker™ SW800 pedometer (F 
= 0.02, P = 0.88), iPhone® lower body (F = 0.12, P = 0.74), iPhone® upper (F = 0.00, P = 0.96) (Table 3).  
Phase 2: Habitual free-living conditions  
Over the seven-day period, visual inspection of the data indicated two significant outliers which 
corroborated with device non-compliance (as per logbook records) and thus eighteen participants 
were included in the analysis (asthma: n = 8; healthy controls: n = 10). No significant difference was 
observed in daily step-count (Yamax Digiwalker™ SW800 pedometer) between participants with 
asthma (7877 ± 2593 steps) and healthy controls (8809 ± 2326 steps) (P = 0.43) and therefore group 
data was pooled for analysis (mean: 8395 ± 2421 steps). No significant difference was observed 
between the Yamax Digiwalker™ SW800 pedometer and iPhone® (P = 0.10) and a strong correlation 
(r = 0.94) and acceptable agreement (mean bias: -343, LOA: -1963 to 1276 steps, error range: 4%) 
was observed. Importantly, analysing data from the ‘best’ day of the week (i.e. highest compliance as 
per logbook records) resulted in a stronger correlation (r = 0.99) and even closer limits of agreement 












bias was identified for the ‘best day’ (F = 5.18, P = 0.04) but not for ‘average days’ (F = 2.00, P = 0.18) 
(Table 3). 
DISCUSSION  
The purpose of this pilot study was to evaluate the validity of modern smartphone technology for the 
assessment of physical activity in adults with and without asthma. In support of the initial hypothesis, 
our findings indicate that an in-built iPhone® pedometer provides an accurate step-count estimate 
during standardised treadmill and self-paced walking challenges and free-living conditions. The 
potential practical application of smartphone pedometers in the context of asthma management can 
therefore be considered three-fold. Firstly, as a simple approach to monitor or promote step-based 
physical activity during medical consultation (i.e. routine asthma review). Secondly, a reduction in 
physical activity may potentially represent an early marker of impending exacerbation that could be 
prevented through a self-management plan. Thirdly, as a research tool or outcome measure when 
utilised in clinical trials.  
The measurement of physical activity is a complex task and thus the development and evaluation of 
scalable and low-cost methods of assessment remains an important research avenue [22]. In-keeping 
with previous comparable studies in healthy individuals [13, 23] the present study confirms that the 
iPhone® (positioned on either the upper or lower body) provides an accurate step-count estimate 
during a standardised laboratory-based treadmill challenge at slow (2.5kph), moderate (5.0kph) and 
high (7.5kph) walking speeds. Specifically, the iPhone® positioned on the lower body (i.e. trouser 
pocket) provided the closest agreement with video-verified manual total step-count, and 
importantly, either matched or outperformed the Yamax Digiwalker™ SW800 pedometer across all 
test stages.  
It has previously been recommended that, to be considered ‘research-grade’ quality, pedometers 
should be within ±1% error range during standardised treadmill-based walking [24]. A key 












Digiwalker™ SW800 pedometer at the slowest walking speed (2.5kph). Many commercially available 
pedometers have a ‘acceleration dependent’ component, meaning they often underestimate step 
count at slower walking speeds [25-27]. In support of this concept, the error rate of the Yamax 
Digiwalker™ SW800 pedometer in the current study improved significantly during moderate (5.0kph) 
and high (7.5kph) walking speeds. Similarly, during self-paced walking (estimated average speed 
approximately 5.0kph) all devices demonstrated excellent agreement with video-verified manual 
step-count. Importantly, regardless of positioning - on either the upper or lower body - the iPhone® 
accurately captured step count across all walking speeds. This highlights the potential benefit of 
using smartphone technology in patients recognised to avoid moderate to vigorous intensity physical 
activity (e.g. people with airways disease) [28] or in cohorts with impaired mobility (i.e. elderly 
individuals +/- those with underlying musculoskeletal disorders) [29].  
The evaluation of pedometers in a real-world setting is important to determine device validity 
according to the specific demands (i.e. walking speeds) of daily tasks. A previous comprehensive 
assessment of 13 models of electronic pedometers, over a 24-hour period, concluded that a ±10% 
variability was an acceptable error range during free-living conditions [30]. Specific to smartphone 
devices, Duncan et al. reported a significant under-estimation of steps when evaluating the iPhone® 
during free-living conditions in healthy individuals (±18% error range in comparison to the Actigraph 
GT3X) [13]. In contrast, the iPhone® exceeded the ±10% criterion [30] (4% error range in comparison 
to the Yamax Digiwalker™ SW800 pedometer) in the current study and improved further when 
selecting the ‘best day’ according to participant compliance over a seven-day period (<1% error 
range). Although the disparity between studies remains unclear, our data indicate that, with optimal 
compliance (i.e. verifying time spent active with logbook records), the iPhone® pedometer can be 
considered a valid method to quantify habitual physical activity. Furthermore, using modern 
smartphone pedometers for this purpose may reduce the impact of participant reactivity given most 
people typically carry their device with them throughout the day. In addition, having reliable and 












self-management of their condition. Importantly, in-built smartphone pedometers report accurate 
scores, minute-by-minute, thus encouraging positive self-surveillance and habit formation. 
 
Methodological considerations and future research  
The present study has two key strengths. Firstly, the iPhone® pedometer was evaluated in both 
standardised and free-living conditions. Secondly, our results are directly compared to those of an 
asymptomatic group of healthy controls. It is important to recognise, however, that despite our 
encouraging findings, due to the current lack of a gold-standard comparator, evaluating the validity 
of any novel physical activity assessment method remains a challenge [11]. Although video-verified 
manual step-count was utilised to verify the accuracy of our data during laboratory and field-based 
walking challenges, a degree of measurement error is inevitable when evaluating step-count during 
habitual free-living conditions. In addition, the current study focused exclusively on the iPhone® 
pedometer (on the basis that it currently exceeds over half of the total smartphone UK market share 
[31]) in a modest sample size and thus a logical extension of this work is to consider inter-device 
variability according to different smartphone brands/models and mobile operating systems in a large 
asthma cohort (i.e. factoring activity profiles according to disease severity and sub-types). 
Notwithstanding these limitations, our data provides the first evidence to suggest that in-built 
smartphone pedometers provide a reliable means of estimating step-count in adults with asthma. 
From a practical perspective, they may therefore be used in future prospective research trials and/or 
retrospective analysis of clinical records to determine the association between physical activity and 
asthma control and/or efficacy of physical activity promotion or behaviour change programmes. This 
is particularly pertinent at present due to the SARS-CoV-2 pandemic where shielding and self 
isolation has had a negative impact on physical engagement for ‘high-risk’ groups and urgent need 













In summary, our findings indicate that an in-built iPhone® pedometer offers a practical approach to 
physical activity assessment (i.e. valid step-count estimate under varying conditions) in adults with 
and without asthma. Future research is now required to further validate the precision of this 
approach and evaluate the efficacy and effectiveness of smartphone pedometers to monitor and 
promote physical activity when employed during medical consultation and/or clinical research trials. 
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Table 1. Clinical characteristics and baseline lung function.  
 
 Healthy Asthma Total 
Age (years) 23 (9) 23 (7) 23 (8) 
Sex (M:F)  6 : 4 6 : 4 12 : 8 
Height (cm) 172 (10.3) 175.3 (8.8) 173.6 (9.5) 
Weight (kg) 74.3 (12.3) 75.4 (11.1) 74.9 (11.4) 
BMI (kg/m
2
) 25.0 (2.5) 24.5 (2.8) 24.7 (2.6) 
Blood pressure (mmHg) 
Systolic  










Resting heart rate (bpm) 70 (14)   71 (13) 71 (13) 
 Fat (%) 20.5 (8.1) 19.7 (7.2) 20.1 (7.5) 
  Fat mass (kg) 16.0 (7.0) 14.8 (6.0) 15.4 (6.4) 
  Fat free mass (kg) 60.3 (13.7) 60.4 (10.5) 60.3 (11.9) 
FEV1 (L) 4.0 (0.8) 3.6 (0.6) 3.7 (0.7) 
FEV1 (%) predicted 104 (8) 90 (12.7)* 97 (12.7) 
FVC (L) 4.6 (1.3) 4.6 (0.90) 4.6 (1.1) 
FVC (%) predicted 104 (8.1) 97 (8.9) 100 (9.1) 
FEV1/FVC (%) 87 (8.5) 79 (12) 83 (10.9) 
PEF (l/min) 531.9 (126.3) 487.5 (92.1) 509.7 (109.9) 
PEF (%) 101.8 (11.8) 97 (11.5) 99.5 (11.6) 
FeNO (ppb) 20 [13 - 32] 36 [19 - 72] 21 [19 - 47]  
ACQ - 1.1 [0.7 - 1.0] - 
AQLQ - 6.1 [5.4 - 6.2] - 
D-12 0 5.5 [1.0 - 10.3] - 
Data presented as mean (SD) and median [IQR]. Definitions of abbreviations: FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; FeNO, 
fractional exhaled nitric oxide; ACQ, asthma control questionnaire; AQLQ, asthma quality of life 












Table 2. Total step-count during standardised treadmill walking.  
Device (speed) Step-count Paired t test ICC  Mean bias  LOA Regression 
  P-value    F-value P-value 
Video-verified manual step-count (2.5kph) 253 (18) -      
  iPhone® upper 242 (42) 0.24 0.33 -11 -89 to 67 16.76 0.00 
  iPhone® lower 253 (21) 0.99 0.77 0 -27 to 27 0.88 0.36 
  Yamax Digiwalker™ SW800 179 (70) <0.0001 0.37 -74 -203 to 55 65.0 <0.0001 
Video-verified manual step-count (5.0kph) 337 (17) -      
  iPhone® upper 336 (18) 0.86 0.88 -1 -17 to 16 0.20 0.59 
  iPhone® lower 333 (16) 0.003 0.96 -4 -14 to 6 0.88 0.36 
  Yamax Digiwalker™ SW800 329 (28) 0.23 0.40 -8 -59 to 44 5.77 0.03 
Video-verified manual step-count (7.5kph) 439 (29) -      
  iPhone® upper 431 (30) 0.009 0.91 -8 -33 to 17 0.05 0.83 
  iPhone® lower 430 (35) 0.009 0.93 -9 -33 to 17 3.95 0.06 
  Yamax Digiwalker™ SW800 433 (31) 0.004 0.97 -6 -20 to 9 0.69 0.42 
Video-verified manual step-count (total) 1028 (56) -      
  iPhone® upper 1009 (67) 0.08 0.74 -19 -108 to 70 1.24 0.28 
  iPhone® lower 1017 (58) 0.006 0.96 -11 -43 to 21 0.36 0.56 
  Yamax Digiwalker™ SW800 942 (99) <0.0001 0.66 -86 -233 to 60 11.47 0.00 














Table 3. Total step-count during self-paced walking and habitual free-living conditions.  
Device Step-count Paired t test ICC Mean bias  LOA Regression 
  P-value    F-value P-value 
1-km self-paced walking test        
Video-verified manual step-count  1406 (146)       
  iPhone® upper 1402 (146) 0.45 0.99 -4 -49 to 41 0.00 0.96 
  iPhone® lower  1393 (149) 0.06 0.98 -13 -67 to 42 0.12 0.74 
  Yamax Digiwalker™ SW800 1394 (148) 0.08 0.98 -12 -66 to 43 0.02 0.88 
Habitual free-living conditions        
Average days         
  Yamax Digiwalker™ SW800 8395 (2421) 
0.10 0.94 -343 -1963 to 1276 2.00 0.18 
  iPhone
®
 8051 (2149) 
Best day         
  Yamax Digiwalker™ SW800  9706 (3712) 
0.31 0.99 -105 -946 to 736 5.18 0.04 
  iPhone
®
 9601 (3500) 


















Figure 1. Bland-Altman plots for iPhone® upper body: (a) 2.5kph, (b) 5.0 kph, (c) 7.5 kph and (d) total 
steps during a standardised treadmill walking test. Closed black circles denote healthy controls; open 
circles denote adults with asthma. 
 
Figure 2: Bland-Altman plots for iPhone® lower body: (a) 2.5kph, (b) 5.0 kph, (c) 7.5 kph and (d) total 
steps during a standardised treadmill walking test. Closed black circles denote healthy controls; open 
circles denote adults with asthma. 
 
Figure 3: Bland-Altman plots for Yamax Digiwalker™ SW800: (a) 2.5kph, (b) 5.0 kph, (c) 7.5 kph and 
(d) total steps during a standardised treadmill walking test. Closed black circles denote healthy 
controls; open circles denote adults with asthma. 
 
Figure 4. Bland Altman plots from 1-km self-paced walking test: (a) iPhone® upper body, (b) iPhone® 
lower body and (c) Yamax Digiwalker™ SW800. Closed black circles denote healthy controls; open 
circles denote adults with asthma. 
 
Figure 5. Bland-Altman plots with 95% limits of agreement from 7-day free living assessment for 
Yamax Digiwalker™ SW800 versus iPhone®: (a) average day and (b) best day. Closed black circles 























































































- 1.96 S.D: -33





































































































































































































































































































































































































































t +1.96 S.D: 1276
Mean bias: -343
-1.96 S.D: -1963
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